TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31464100

Group type: EXPERIMENTAL
Intervention: Nutritional care as per the algorithm (oral supplements, nasogastric feeds, and/or parenteral nutrition)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Institutional standard of care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nutritional care as per the algorithm
Number of subjects: 50
Study: 31304457

Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 669
Study: 27525497

Group type: EXPERIMENTAL
Intervention: Conservative treatment (supination sugar-tong splinting)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Operative treatment (DRUJ transfixation)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Operative treatment (arthroscopic triangular fibrocartilage complex repair)
Number of subjects: 157
Study: 24887458

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (HT)
Number of subjects: 137
Study: 22030444

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study: 19882460

Group type: EXPERIMENTAL
Intervention: Participation in research
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug users not participating in the research
Number of subjects: 0
Study: 17456522

Group type: EXPERIMENTAL
Intervention: Health services intervention to train health personnel in TB testing and isoniazid prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (clinics not receiving the intervention)
Number of subjects: 0
Study: 15988586

Group type: EXPERIMENTAL
Intervention: 50 mAs (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 100 mAs (Group B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 130 mAs (Group C)
Number of subjects: 75
Study: 12213743

Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine administration (bolus followed by 6 hours infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10452769

Group type: EXPERIMENTAL
Intervention: Active air cleaners
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham air cleaners
Number of subjects: 20
Study: 8591798

Group type: EXPERIMENTAL
Intervention: Single-dose L-dopa/benserazide (300/75 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 29
Study: 2677988

Group type: EXPERIMENTAL
Intervention: Radiation therapy for bone metastasis
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Radiation therapy for lung cancer patients with bone metastasis
Number of subjects: 131
Study: 934556

Group type: EXPERIMENTAL
Intervention: T-tube suction drainage alone
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics alone
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: T-tube suction drainage and prophylactic antibiotics in combination
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 451
Study: 31739177

Group type: EXPERIMENTAL
Intervention: TruvadaⓇ-PrEP (tenofovir and emtricitabine)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Chemsex engagement
Number of subjects: 544

Group type: COMPARATOR
Intervention: <7/7 intended doses (ID)
Number of subjects: 544
Study: 27908896

Group type: EXPERIMENTAL
Intervention: Written patient-targeted feedback
Number of subjects: 375

Group type: COMPARATOR
Intervention: No written patient feedback (control group)
Number of subjects: 375
Study: 26957979

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Resistance exercise training
Number of subjects: 100
Study: 24365779

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 27
Study: 21480321

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 50
Study: 19622782

Group type: EXPERIMENTAL
Intervention: Low-dose rosiglitazone (4 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose rosiglitazone (8 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose metformin (2,000 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose combination rosiglitazone-metformin therapy (4 mg + 1,000 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose rosiglitazone-metformin combination therapy (8 mg + 2,000 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 0
Study: 15672555

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.5 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lorazepam 1.0 mg
Number of subjects: 22
Study: 10915412

Group type: EXPERIMENTAL
Intervention: DCLHb (10% diaspirin cross-linked hemoglobin)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 139
Study: 7488475

Group type: EXPERIMENTAL
Intervention: Extradural morphine 2 mg (group M)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% lignocaine 10 ml (group L)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of morphine 2 mg and 2% lignocaine 10 ml (group ML)
Number of subjects: 24
Study: 2048820

Group type: EXPERIMENTAL
Intervention: Furosemide (30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bumetanide (2 mg)
Number of subjects: 16
Study: 6167346

Group type: EXPERIMENTAL
Intervention: Platinum, vinblastine, and bleomycin
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Lower dosage of vinblastine (0.3 mg/kg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Maintenance vinblastine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Four courses of remission induction therapy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High cure rate in Stage B disease
Number of subjects: 137
Study: 30447984

Group type: EXPERIMENTAL
Intervention: INFIX
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pelvic Bridge
Number of subjects: 10

Group type: COMPARATOR
Intervention: APEF (anterior pelvic external fixation)
Number of subjects: 10
Study: 27488572

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 29
Study: 26375942

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg once daily for 2 weeks followed by raltegravir 400 mg twice daily for 5 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily for 5 days
Number of subjects: 24
Study: 24820225

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (10 Hz)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 22650964

Group type: EXPERIMENTAL
Intervention: Oral administration of vitamin B12 (1 mg/day in weeks 1-8 and 1 mg/week in weeks 9-52)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Intramuscular administration of vitamin B12 (1 mg on alternate days in weeks 1 and 2, 1 mg/week in weeks 3-8, and 1 mg/month in weeks 9-52)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both oral and intramuscular administration
Number of subjects: 320
Study: 19541525

Group type: EXPERIMENTAL
Intervention: Needling Fragmentation Irrigation (NFI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bursoscopy (BS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 96
Study: 17305711

Group type: EXPERIMENTAL
Intervention: Occlusal splint (OS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 57
Study: 15067411

Group type: EXPERIMENTAL
Intervention: Optical rhinometry during positive nasal provocation tests with histamine and allergens
Number of subjects: 15

Group type: COMPARATOR
Intervention: Optical rhinometry during negative provocation tests with allergens in non-allergics
Number of subjects: 15

Group type: COMPARATOR
Intervention: Optical rhinometry during negative provocation tests with control solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Optical rhinometry during decongestion with xylometazoline
Number of subjects: 15
Study: 11233800

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg orally for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (matched, once daily for 7 days)
Number of subjects: 10
Study: 9641172

Group type: EXPERIMENTAL
Intervention: Low protein diet intervention
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low blood pressure intervention
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Younger women
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Older women
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Overall GFR decline
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of study A
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Full cohort analysis
Number of subjects: 840
Study: 7928327

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-relaxation
Number of subjects: 23
Study: 29694272

Group type: EXPERIMENTAL
Intervention: Mouthguard
Number of subjects: 24

Group type: COMPARATOR
Intervention: No mouthguard
Number of subjects: 24
Study: 28512184

Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (target SBP <120 mm Hg)
Number of subjects: 8164
Study: 26281833

Group type: EXPERIMENTAL
Intervention: Standard dose of 1.0 Gy applied in 6 fractions of 1.0 Gy twice weekly (total dose 6.0 Gy)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low single doses of 0.5 Gy applied in 12 fractions of 0.5 Gy three times weekly (total dose 6.0 Gy)
Number of subjects: 127
Study: 23530977

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Strict control (target SBP <130 mm Hg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mild control (target SBP 130-139 mm Hg)
Number of subjects: 80
Study: 21444210

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 2086
Study: 19686527

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Brief Advice
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: MET + Cognitive-Behavioral Therapy (CBT)
Number of subjects: 117
Study: 17942927

Group type: EXPERIMENTAL
Intervention: Zanolimumab (human IgG1 antibody against CD4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanolimumab
Number of subjects: 0
Study: 15562884

Group type: EXPERIMENTAL
Intervention: Combined ibuprofen/pseudoephedrine/chlorpheniramine (200/30/2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined ibuprofen/pseudoephedrine/chlorpheniramine (400/60/4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined pseudoephedrine/chlorpheniramine (30/2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11146707

Group type: EXPERIMENTAL
Intervention: Combined outreach initiative for pneumococcal and influenza vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pneumococcal vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined outreach initiative targeted to people who had never received the pneumococcal vaccine or who had not received the influenza vaccine in the previous year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined outreach initiative as implemented
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted initiative
Number of subjects: 0
Study: 9623896

Group type: EXPERIMENTAL
Intervention: Group A: demineralized freeze-dried allograft, tetracycline, and porous hydroxyapatite
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group B: demineralized freeze-dried allograft and tetracycline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Defects with > or =10 mm probing depths in Group A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Defects with > or =10 mm probing depths in Group B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Defects with <10 mm probing depths in Group A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Defects with <10 mm probing depths in Group B
Number of subjects: 100
Study: 7870348

Group type: EXPERIMENTAL
Intervention: Controlled Protein Diet (CPD) of 1 g protein/kg ideal body-weight/day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Low-Protein Diet (LPD) of 0.6 g protein/kg ideal body-weight/day
Number of subjects: 128
Study: 3351998

Group type: EXPERIMENTAL
Intervention: Ender nails
Number of subjects: 100

Group type: COMPARATOR
Intervention: McLaughlin technique (nail-plate fixation)
Number of subjects: 100
Study: 29130570

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) at 10°C for 10 minutes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Partial-body cryotherapy (PBC) at -60°C for 30 seconds and -135°C for 2 minutes
Number of subjects: 19
Study: 28166654

Group type: EXPERIMENTAL
Intervention: VM202 (64 mg) administered by intramuscular injections on days 0, 7, 14, and 21.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VM202 (64 mg) administered by intramuscular injections.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VM202 treatment.
Number of subjects: 18
Study: 25672853

Group type: EXPERIMENTAL
Intervention: No-show patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 105
Study: 24004897

Group type: EXPERIMENTAL
Intervention: Telephone-based support for breastfeeding (6 months duration)
Number of subjects: 226
Study: 21931228

Group type: EXPERIMENTAL
Intervention: Tartary buckwheat cookies (359.7 mg rutin equivalents/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Common buckwheat cookies (16.5 mg rutin equivalents/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both types of buckwheat cookies
Number of subjects: 62
Study: 18245308

Group type: EXPERIMENTAL
Intervention: Novel empirical disability weights for injury consequences
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Application of novel empirical disability weights
Number of subjects: 143
Study: 16879471

Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning (head-down group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine position (supine group, n = 15)
Number of subjects: 30
Study: 12805245

Group type: EXPERIMENTAL
Intervention: Roasted salted almonds
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Roasted almond butter
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Raw almonds
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no almonds)
Number of subjects: 38
Study: 11054354

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (5 microgram of recombinant hepatitis B vaccine, Engerix B) every 2 weeks up to a peak Ab titer of 1,000 IU/L or greater or 52 doses
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intramuscular vaccination (40 microgram at 0, 1, 2, and 6 months)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intramuscular vaccination with peak Ab titer of 1,000 IU/L or greater
Number of subjects: 97
Study: 8866093

Group type: EXPERIMENTAL
Intervention: Aprotinin (high doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 1339712

Group type: EXPERIMENTAL
Intervention: Allopurinol (oral, preoperatively)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no allopurinol)
Number of subjects: 18
Study: 6391936

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cisapride 4 mg (IV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cisapride 8 mg (IV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg (IV)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 31608548

Group type: EXPERIMENTAL
Intervention: Basal insulin glargine 100 U/mL (Gla-100)
Number of subjects: 2165
Study: 29498534

Group type: EXPERIMENTAL
Intervention: Nocturnal dexmedetomidine (0.2 μg/kg/h, titrated by 0.1 μg/kg/h every 15 min until a goal Richmond Agitation and Sedation Scale score of -1 or maximum rate of 0.7 μg/kg/h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nocturnal dexmedetomidine
Number of subjects: 100
Study: 27355400

Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 24468725

Group type: EXPERIMENTAL
Intervention: Canonical body posture (extended forearm and hand pointing distally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-canonical body posture (forearm and hand pointing vertically up at 90°)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversed body posture (elbow fully flexed at 180°)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversing the canonical posture of the finger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canonical orientation in egocentric space
Number of subjects: 0
Study: 22668427

Group type: EXPERIMENTAL
Intervention: 5 mg allicin adhesive tablets
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vehicle only (placebo)
Number of subjects: 96
Study: 19910620

Group type: EXPERIMENTAL
Intervention: Single-injection peribulbar anesthesia with a 16-mm needle
Number of subjects: 200

Group type: COMPARATOR
Intervention: Double-injection peribulbar anesthesia with a 25-mm needle
Number of subjects: 200
Study: 17409102

Group type: EXPERIMENTAL
Intervention: Electric breast pump
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Non-electric pedal breast pump
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hand (manual) expression
Number of subjects: 65
Study: 15472677

Group type: EXPERIMENTAL
Intervention: Pure-cut electrosurgical current
Number of subjects: 246

Group type: COMPARATOR
Intervention: Blend electrosurgical current
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 246
Study: 11505257

Group type: EXPERIMENTAL
Intervention: Unilateral inferior alveolar nerve block
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bilateral inferior alveolar nerve block
Number of subjects: 38
Study: 9620807

Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8140047

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg administered orally
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg administered to the colon via nasogastric intubation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg administered rectally using a retention enema
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nonparenteral routes (oral, colonic, rectal)
Number of subjects: 6
Study: 2846971

Group type: EXPERIMENTAL
Intervention: Intensive outpatient care with close monitoring, appointment reminders, and rescheduling of missed visits.
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1001
Study: 31844958

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: ICA
Number of subjects: 226
Study: 30621622

Group type: COMPARATOR
Intervention: Low-dose aspirin once per day (Group A)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin and 4.0 g of ecabet sodium (Group B)
Number of subjects: 2
Study: 27714572

Group type: EXPERIMENTAL
Intervention: Transconjunctival single‐plane sclerocorneal incisions (TSSI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Clear corneal incisions (CCI)
Number of subjects: 64
Study: 26742006

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily for 2 or 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with triple-negative and AR+ tumours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with AR- tumours
Number of subjects: 0

Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 0
Study: 24668760

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 57
Study: 22583535

Group type: EXPERIMENTAL
Intervention: Drinking reduction strategies during treatment
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Booster sessions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Baseline heavy drinking days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Baseline abstinent/light drinking days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Drinking reduction strategies
Number of subjects: 144
Study: 19918752

Group type: EXPERIMENTAL
Intervention: Pulse high volume hemofiltration (pHVHF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of pHVHF and CPFA
Number of subjects: 8
Study: 17242082

Group type: EXPERIMENTAL
Intervention: Magnetic therapy (n = 81)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sham therapy (n = 84)
Number of subjects: 165
Study: 16075030

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering using a fixed low-dose combination of perindopril and indapamide
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Intensive gliclazide-MR-based glucose control regimen
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Combined effects of more intensive glucose control and tighter control of blood pressure
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo for blood pressure lowering
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard guidelines-based glucose control regimen
Number of subjects: 11140